MS
Satellos Bioscience Inc.
MSCL.TO · TSX
$10.77 -6.35% (-$0.73)
1M -15.66%
Market Cap $157.8M
P/E Ratio -
Div. Yield -
ROE 71.28%
Bulios Fair Price
$8.54
20.7% downside
Current Price
$10.77
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MSCL.TO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
73 /100
Cheap P/B 2.64x
P/FCF N/A
P/FFO N/A
Growth
100 /100
Growing Book val. growth 101.91%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROA 52.18%
ROIC 59.83%
Debt
100 /100
Low Current ratio 11.22x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
46 /100
Moderate EPS volatility 43.08%
Profitable years 0
Beta 1.14x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MSCL.TO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Francis Gleeson
Employees
18
Headquarters
Toronto
Upcoming events
12 NOV
Earnings
Upcoming earnings report